Serial proteomic analysis identifies small extracellular vesicle-MASP2 as an early biomarker of chemotherapy response in advanced pancreatic cancer.

ABSTRACT:

Background

The average survival of advanced pancreatic cancer (APC) is 6-12 months with first-line chemotherapy. Only one-third receive second-line treatment. No early biomarker exists to guide chemotherapy efficacy before tumor progression occurs. Circulating small extracellular vesicles (sEVs) are a potential source of biomarker discovery.

Methods

Longitudinally collected sEVs from chemotherapy treated APC patients at pre-treatment, remission and relapse underwent proteomic profiling by mass spectrometry (MS). GO and KEGG analyses assessed differential protein characteristics, while protein-protein interactions and upstream analyses explored potential mechanisms. A candidate biomarker was validated by ELISA in larger patient cohorts of responders and non-responders. Gene k

SUBMITTER: Dey S 

PROVIDER: S-EPMC12756548 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature